Inmunoterapia con células CAR-T en hematooncología pediátrica

Mirones, Isabel; Moreno, Lucas; Patiño-García, Ana; Lizeaga, Garbiñe; Moraleda, José M; Toribio, María Luisa; Pérez-Martínez, Antonio.
An. pediatr. (2003. Ed. impr.) ; 93(1): 59.e1-59.e10, jul. 2020. tab
Artículo en Español | IBECS (España) | ID: ibc-199872

Documentos relacionados

  1. [Immunotherapy with CAR-T cells in paediatric haematology-oncology].
  2. CAR-T Cell Therapies: An Overview of Clinical Studies Supporting Their Approved Use against Acute Lymphoblastic Leukemia and Large B-Cell Lymphomas.
  3. Durable remissions achieved with reinfusion of CD19-directed CAR-T despite failure to induce or maintain B-cell aplasia and single-center experience with reinfusion of tisagenlecleucel.
  4. A systematic review on the cost-effectiveness assessment of tisagenlecleucel for refractory or relapsing B-cell acute lymphoblastic leukemia (R/R B-ALL) treatment in children and young adults.
  5. Tisagenlecleucel for treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
  6. The CAR T-cell race: The rules of the game.
  7. Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy.
  8. CD19 CAR T Cells.
  9. Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy.
  10. Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia.